Home

 

1055 Westlakes Drive

Suite 200

Berwyn, PA 19312

© 2018 Complexa. All rights reserved.

  • LinkedIn - Grey Circle

Board of Directors

Please reload

 
 
 
 
 
 

Chairman

David Mott has served as Chairman of the Complexa Board of Directors since 2017. He currently serves as a General Partner for New Enterprise Associates (NEA) and leads the healthcare investing practice, which typically comprises roughly one-third of each fund, or $1.1 billion of healthcare venture investments every two-to-three years. Prior to joining NEA, David was President and Chief Executive Officer of MedImmune, a subsidiary of AstraZeneca Plc, and Executive Vice President of AstraZeneca. David joined MedImmune in 1992 and served in various leadership and senior management roles from 2000 to 2008, including President and Chief Executive Officer, Chief Financial Officer, and President and Chief Operating Officer. He led the sale of MedImmune to AstraZeneca in June 2007 for $15.6 billion. Prior to joining MedImmune, David was a Vice President in Health Care Investment Banking at Smith Barney, Harris Upham & Co., Inc. where he focused on public and private equity and debt financings as well as mergers and acquisitions. He received a BA in Economics and Government from Dartmouth College. In addition to Complexa, David is currently Chairman of 3-V Biosciences, Adaptimmune (NASDAQ: ADAP), Ardelyx (NASDAQ: ARDX), Cydan, Epizyme (NASDAQ: EPZM), Imara, Mersana (NASDAQ: MRSN), and TESARO (NASDAQ: TSRO), and is a director of Clementia, Nightstar and Xtuit.

Director

Barbara Dalton, PhD, has been a member of Complexa’s Board of Directors since 2017. She joined Pfizer in 2007 to manage the Pfizer Ventures Investments (PVI) team within the Worldwide Business Development organization. Barbara has 24 years of corporate venture capital experience in the pharmaceutical industry supporting and managing teams involved in direct and indirect healthcare investing. She has had management responsibility for over 100 diverse company investments and 30 fund investments in both the US and Europe. Barbara began her pharmaceutical career as a research scientist in Immunology at SmithKline and French Laboratories in 1983 and joined their venture capital group, S.R. One, Limited ten years later. Barbara was also a founding member and General Partner with EuclidSR Partners, a private venture capital firm, where SmithKline (now GSK) was a leading limited partner. She has been on the board of academic groups, not-for-profit foundations and industry organizations in her role as a member of the BioPharma ecosystem in both the Philadelphia and New York communities. Barbara is a graduate of Penn State and received her PhD in Microbiology and Immunology from The Medical College of Pennsylvania (now the Drexel University College of Medical School).

Director

Kenji Harada, PhD, has served on Complexa’s Board of Directors since 2012. He has more than 20 years of experience in evaluating medical drug candidates, scientific technology platforms and intellectual property portfolios. In addition to Complexa, Kenji also served on the board of TRACON Pharmaceuticals and Eleven Biotherapeutics. In 2004, he joined JAFCO, the largest venture capital firm in Japan, working for the life science investment group as a group leader. In this role, he evaluates US or Japan-based biotech companies for potential investment opportunities, several of which have successfully gone on to become public companies or the subject of significant acquisitions. Prior to JAFCO, Kenji held positions of increasing responsibility within the medical drug and devices division of Toray Industries, Inc., a leading Japanese chemical and fiber company, most recently as manager for collaborative research agreements with a number of leading Japanese academic institutes and biotechnology companies. He is an immunologist by training, earning his PhD in pharmacology at the University of Tokyo.

Director

Ben Machielse joined Complexa’s Board of Directors in 2018. He has more than 25 years of experience in the biotech industry. Ben has been involved with the successful development of multiple drugs, including the first H1N1 vaccine available to the public in the United States. Most recently, Ben served as Chief Executive Officer of Vtesse, a company developing treatments for Niemann Pick Disease. After completion of its pivotal clinical study, the company was acquired in April 2017 by Sucampo Pharmaceuticals. Prior to Vtesse, Ben served as Chief Operating Officer of Omthera Pharmaceuticals, where he was responsible for the development and approval of a drug for the treatment of hypertriglyceridemia. He was also integral in the acquisition of Omthera by AstraZeneca. Ben also served as Executive Vice President of Operations for MedImmune, spending 11 years there. In this role, he led the worldwide development and operations of MedImmune’s therapeutic antibodies, small molecules and vaccine products. Previously, Ben held executive roles within product development, quality and operations at Xoma Corporation and Centocor BV. He has served on the boards of Xencor, Inc. and Tetragenetics, Inc., and is currently a member of the Scientific Advisory Board of the Ara Parseghian Medical Research Foundation and a board member of Comet Therapeutics. Ben holds a Bachelor of Science in Medical Biology and a Master’s in Biochemistry from the University of Utrecht in the Netherlands.

Director

I. Wistar Morris has served on the Complexa Board of Directors since 2012. He is Senior Investment Consultant to Pennsylvania Trust. In April 2011, he retired from Boenning & Scattergood, an Investment Securities firm, where he served as a Director and Investment Advisor for 20 years. Prior to this, Wistar founded the Morris Investment Management Company and held the roles of President and Chairman. He was also Executive Vice President with the investment management firm Hopper Soliday & Co., spending 15 years there. Wistar has been on the boards of 20 public and private companies. He is also the Founder and CEO of The Cotswold Foundation and the author of Adventures in Investing, which describes his career in the investment business. Wistar received a bachelor’s degree in Chemistry from Cornell University, an MBA from the Harvard Business School, and holds the CFA designation from the CFA Institute.

Director

 

Sara Nayeem, MD, has been a member of Complexa’s Board of Directors since 2017. She is a Partner at New Enterprise Associates (NEA), joining the healthcare team in 2009 and focusing on investments in biopharmaceutical companies. Prior to joining NEA, she was an Associate with Merrill Lynch’s Global Healthcare Group, where she advised biotechnology, pharmaceutical and medical device companies on numerous mergers, acquisitions and financing transactions. Previously, Sara worked as an Investment Banking Analyst at Morgan Stanley. In addition to Complexa, she serves on the boards of Mersana (MRSN), Cydan and Imara, and as a board observer for Clementia, Millendo and NightstaRx. Sara previously served on the board of Vtesse (acquired by Sucampo) and as a board observer for Tesaro (TSRO), Ziarco (acquired by Novartis), Loxo Oncology (LOXO), Omthera (acquired by AstraZeneca), Epizyme (EPZM) and Zyngenia. She has been selected three times as one of GrowthCap’s Top 40 Under 40 Growth Investors. Sara concurrently earned her MD (cum laude) and MBA from Yale University, where she was a Yale MBA Scholar. She received her AB (magna cum laude) in Biology from Harvard University.

Director

 

Gilles Nobécourt has been a member of Complexa’s Board of Directors since 2017. He joined Edmond de Rothschild Investment Partners in 2002. Previously, he was a consultant with Russell Reynolds & Associates dedicated to pharmaceutical and biotechnology companies. He has a diverse background having served in a number of government and agency roles in France, including Advisor to the French Minister for Industry and Research and Advisor to the French Prime Minister. He also held the position of Field Officer for the United Nations High Commissioner for Refugees in Africa and Central America until 1989, when he joined Rhône-Poulenc Group as Vice President, Public Affairs. In 1992, he was appointed Vice President, assistant to the Chairman and CEO of Rhône-Poulenc Rorer. Gilles later became a founding member of RPR Gencell, the biotechnology division of Rhône-Poulenc Rorer. He subsequently was promoted to deputy General Manager of the Division based in San Francisco until 1999. In addition to the Complexa board position, Gilles is a director of Genkyotex, Complix, Gamamabs, Inotrem, Fondation Ophtalmologique Adolphe de Rothschild and Managing Partner of EdRIP. A graduate of the Paris Institute for Political Sciences (‘Sciences Po Paris’), Gilles also holds a master’s degree in Applied Economics and a certificate from the Stanford Global School of Business.

Director

Francisco D. Salva serves as Chief Executive Officer and President. He has more than 20 years of experience in corporate development, operations, healthcare venture capital and investment banking. Prior to joining Complexa, Mr. Salva served as a Founder and Vice President of Operations for Acerta Pharma B.V., where he focused on key growth initiatives culminating in a $4 billion investment by AstraZeneca for a controlling ownership interest. While at Acerta Pharma, Mr. Salva was responsible for the company’s financial and operational activities. His responsibilities included deal analysis and negotiations, investor relationships, partnership compliance and financings. Prior to Acerta, he was Senior Director of Corporate Development at Pharmacyclics. Earlier in his career, Mr. Salva spent almost a decade as a life sciences venture capitalist at CIBC Capital Partners, INVESCO Funds Group and Patricof & Co. Ventures. He began his career at Wasserstein Perella & Co.Mr. Salva holds dual Bachelor of Arts degrees in Business Economics and Philosophy from Brown University and a Master of Science degree in Economics (Economics and Philosophy specialty) from the London School of Economics and Political Science.

Please reload

 
 
Heading 6